A popular feature of Suze's show is called "Can I Afford It?" In this segment, callers from all over the United States phone in to ask Suze's permission to purchase indulgences that may range from a Maltese puppy to a deluxe gas grill to a $30 000 anniversary trip. After challenging the caller to, "Show me the money, girlfriend!" (or boyfriend!), Suze reviews their monthly income, savings, debt, and other financial information. Without hesitation, she culminates her review in a resounding crescendo of "You are denied!" or, less often, "Approved!" Suze slices through the emotional attachment of callers to the object of their desire and pares the decision back to a simple calculation of dollars and cents.
"Can we afford it?" is not a question that orthopaedic sports medicine specialists ask very often. We greet every new technological advance with justifiable enthusiasm, yet we rarely inquire about the cost. In a 2005 review of cost-utility analyses in orthopaedic surgery, only 5 of 37 studies were classified as sports medicine. 1 Nevertheless, depending on whatever health care reimbursement system exists in our locality, either our patients or society as a whole must pony up the added expense of each technological advance. In "Cost Analysis of Converting from Single-Bundle to Double-Bundle Anterior Cruciate Ligament Reconstruction," which appeared in the April issue of AJSM, Brophy et al 2 looked at the potential cost of implementing a surgical technique that has attracted nearly as many passionate supporters and detractors as Suze Orman.
The first goal of the study was to estimate the added cost incurred if some or all anterior cruciate ligament (ACL) reconstructions in the United States were performed with a double-bundle technique instead of the single-bundle method. Working from an assumption that 200 000 ACL reconstructions are carried out in the United States each year, the authors calculated the total added cost under 5 different scenarios that varied in the percentage of penetration of conversion to double bundle, the amount of additional fixation hardware needed, the number of allografts, if any, that would be used, and the possibility of increased operating room time. The added cost ranged from $36.2 million to $792.4 million, depending on the assumptions of each scenario.
The second step in the analysis was to calculate how many revision procedures would need to be avoided to offset the additional up-front expense. Using actual cost data from their own institution, the authors computed the direct cost of a revision to be about $20 000. They discounted this expenditure at 5% per year and assumed that the average time to revision would be 4 years. The results were quite sobering. Under the most optimistic scenario, the revision rate would need to be reduced by 2.5% to offset the additional up-front investment. Given that a recent systematic review reported an expected revision rate of 4% for primary ACL reconstructions, 11 such a reduction would be possible. However, the more costly scenarios would require the assumption of a much higher revision rate, ranging up to an implausible 24.1%, that would have to be completely eliminated to offset the initial incremental cost of the double-bundle procedures. A sensitivity analysis that lowered the mean revision time to 2 years or raised the price of the revisions to $40 000 made the achievement of cost neutrality more possible but still unlikely. Special populations with a higher expected failure rate, such as young competitive athletes, might be exceptions.
Although these writers were careful to use actual costs and to investigate a large number of permutations, their study still has some limitations. The model was not designed to account for potential secondary cost savings in areas such as physical therapy, loss of patient productivity during convalescence, or the impact of late-developing osteoarthritis on productivity and quality of life. They felt that there is just not enough available data demonstrating clinical differences between single-and double-bundle ACL reconstruction methods to conduct a formal cost-utility analysis comparing the 2 techniques.
Of course, a new treatment does not have to be costneutral to warrant implementation. The potential gain in human health and happiness may be enough to justify the added expense. Such value judgments can be informed by a cost-effectiveness analysis. A cost-effectiveness or costutility analysis requires estimating the perceived benefit of the intervention by soliciting the opinions of potential patients. 1 Most commonly, the benefit is then quantified in units called quality-adjusted life years (QALYs). This allows the calculation of a cost-effectiveness ratio, the value added by a treatment technique for each new dollar or other monetary unit spent. 1, 4 Needless to say, such analyses are complex, 13 require numerous assumptions, and can be controversial. 4, 10 In fact, a cost-effectiveness analysis of single-bundle ACL reconstruction was published in 1999. 5 Using cost data from the Hughston clinic and calculating the benefits based on the literature available at that time, Gottlob et al 5 compared surgical reconstruction with nonoperative treatment of an ACL tear in a young patient. Limiting their analysis to the first 7 years after treatment, the authors concluded that reconstruction would add 1.61 more QALYs than nonoperative management at an incremental cost of $5857 per QALY. Considering that 1 contemporary standard noted that technologies costing less than C$20 000 per QALY were almost universally accepted and that those in the C$20 000 to C$100 000 range were provided routinely, 7 the authors concluded that ACL reconstruction was a QALY bargain. If double-bundle ACL reconstruction is ultimately shown to provide additional benefit to some or all patients, it will be possible to perform a similar calculation to see how much "value for money" is being added.
Suze Orman likes to end her telecasts with the philosophical tagline, "Remember: People first, then money, then things." Surgeons are also trained to put people before money. When faced with an individual patient requiring our help, we naturally want to do whatever is best for that patient, regardless of the cost. 6 Doing otherwise would raise serious ethical concerns. 12 Even insurers and governments shy away from basing their decisions on solely economic grounds. 3, 8, 9 Nevertheless, knowledge is power. Our first consideration in adopting a new treatment should be its effectiveness, but it is responsible behavior to be aware of its expense as well. As the incremental costs of technological innovations accumulate, eventually they add up to real money. Although people and their leaders should agree that few things are as precious as health, resources are ultimately limited. Faced with the continually rising cost of health care, someday someone, whether our patients, their insurers, or their governments, is going to say, "Show me the money!" Bruce Reider, MD Chicago, Illinois
